National urothelial carcinoma registry for recording and improving the quality of care across sectors

National urothelial carcinoma registry for recording and improving the quality of care across sectors - d-uo-UroNAT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00026204

Enrollment

6150

Registered

2021-08-27

Start date

2021-10-19

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C67 C65 C66 C68

Interventions

Group 1: Documentation of diagnostics, therapy and course of disease

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Men and women with a new diagnosis of urothelial carcinoma since Jan. 1, 2021. - Age >= 18 years

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
The registry will investigate the following questions and provide evidence through the data collected: Adherence to guidelines 1) Medical guidelines still play too small a role in outpatient tumor therapy of urologic malignancies and lead to improved outcome with improved adherence (Fröhner M, et al., 2014; Nothacker M, et al., 2014; Busch J, et al., 2010; Lebentrau S, et al., 2016). Endpoint: overall survival (OS) and cancer-specific survival (CSS) stratified by guideline adherence. No evaluation of individual drugs is sought. Risk factors for urothelial carcinoma 2) Nicotine and occupational exposures are insufficiently considered as risk factors in urothelial carcinoma in daily practice (Nowak D, et al., 2008). Endpoint: ascertainment of nicotine abuse and occupational noxae per new diagnosis of urothelial carcinoma. Therapy of non-muscle-invasive urothelial carcinoma 3) After diagnosis of non-muscle invasive bladder carcinoma, according to the S3 guideline, a risk classification of the tumor (low, intermediate, high risk) should be performed according to the risk of recurrence and progression according to the EORTC criteria. The implementation of this recommendation is not known. Endpoint: proportional frequency of performing risk classification according to EORTC criteria. 4) The reality of performing transurethral tumor resections/post-resections according to guidelines has not been investigated in Germany. Endpoint: frequency of performing transurethral tumor resections/post-resections in accordance with or deviating from the national S3 guideline. 5) The reality of guideline-compliant performance of early instillation or adjuvant instillation therapy with chemotherapy or immunotherapy is not known. Endpoint: frequency of performing early instillation or adjuvant instillation therapy with chemotherapies or immunotherapies in accordance with or deviating from the national S3 guideline. 6) The use of fluorescence diagnostics in the context of transuret	—

Measure

Time frame

The registry will investigate the following questions and provide evidence through the data collected: Adherence to guidelines 1) Medical guidelines still play too small a role in outpatient tumor therapy of urologic malignancies and lead to improved outcome with improved adherence (Fröhner M, et al., 2014; Nothacker M, et al., 2014; Busch J, et al., 2010; Lebentrau S, et al., 2016). Endpoint: overall survival (OS) and cancer-specific survival (CSS) stratified by guideline adherence. No evaluation of individual drugs is sought. Risk factors for urothelial carcinoma 2) Nicotine and occupational exposures are insufficiently considered as risk factors in urothelial carcinoma in daily practice (Nowak D, et al., 2008). Endpoint: ascertainment of nicotine abuse and occupational noxae per new diagnosis of urothelial carcinoma. Therapy of non-muscle-invasive urothelial carcinoma 3) After diagnosis of non-muscle invasive bladder carcinoma, according to the S3 guideline, a risk classification of the tumor (low, intermediate, high risk) should be performed according to the risk of recurrence and progression according to the EORTC criteria. The implementation of this recommendation is not known. Endpoint: proportional frequency of performing risk classification according to EORTC criteria. 4) The reality of performing transurethral tumor resections/post-resections according to guidelines has not been investigated in Germany. Endpoint: frequency of performing transurethral tumor resections/post-resections in accordance with or deviating from the national S3 guideline. 5) The reality of guideline-compliant performance of early instillation or adjuvant instillation therapy with chemotherapy or immunotherapy is not known. Endpoint: frequency of performing early instillation or adjuvant instillation therapy with chemotherapies or immunotherapies in accordance with or deviating from the national S3 guideline. 6) The use of fluorescence diagnostics in the context of transuret

—

Secondary

Measure	Time frame
please refer to primary outcome	—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026